Paula Calvert - Concepedia

Author

Paula Calvert

Also Known As

P Calvert, P. Calvert, P. M. Calvert, P., Calvert, P.M Calvert, P.M. Calvert, Paula Calvert, Paula M Calvert, Paula M. Calvert

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Cancer Trials Ireland University Hospital Waterford Seoul National University Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Kliniken Essen-Mitte

About

Paula Calvert is an author at Cancer Trials Ireland specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	173
2	Health Sciences	3	3	68
3	Family Medicine	1	1	25
4	Geriatrics	1	1	25
5	Health Policy	1	1	25

Paula Calvert

Publications

944

Citations

H-Index

Page 1

	Year	Citations
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer Andreas du Bois, Anne Floquet, Jae‐Weon Kim, Journal of Clinical Oncology	2014	318
Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma Andy Hughes, Paula Calvert, Ashraf Azzabi, Journal of Clinical Oncology	2002	148
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer Ignace Vergote, Andreas du Bois, Anne Floquet, Gynecologic Oncology	2019	67
European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Pharmaceutical Companies Ignace Vergote, Éric Pujade-Lauraine, Sandro Pignata, International Journal of Gynecological Cancer	2010	46
Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation? Jarushka Naidoo, Min Yuen Teo, Sandra Deady, Journal of Thoracic Oncology Radiation TherapyMedicineClinical Radiation OncologyOncologyRadiation Oncology	2013	45
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study Roisin E. O’Cearbhaill, José Alejandro Pérez Fidalgo, Bradley J. Monk, Gynecologic Oncology	2022	36
Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial Anne Floquet, Ignace Vergote, Nicoletta Colombo, Gynecologic Oncology Progression-free SurvivalMedicineGynecologyAgo-ovar16 TrialComparative Analysis	2014	32
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy Michael Friedländer, Jörn Rau, Chee Khoon Lee, Annals of Oncology	2017	29
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Ruth Plummer, Michele Ghielmini, Paula Calvert, PubMed	2002	28
Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer. Corey J. Langer, David R. Gandara, Paula Calvert, PubMed	1999	25

Page 1